Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
- Conditions
- Chemotherapy-induced Nausea and Vomiting (CINV)
- Interventions
- Drug: Granisetron transdermal patchDrug: PalonosetronDrug: AprepitantDrug: FosaprepitantDrug: Dexamethasone
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 140
- Registration Number
- NCT04912271
Impact of Steroids on Inflammatory Response in Covid-19
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT04909918
- Locations
- 🇪🇬
Assiut university hospital, Assiut, Assuit, Egypt
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT04910568
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸City of Hope - Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States
Efficacy of Dexamethasone in Attenuation of Postinduction Hypotension in Geriatric Patients Undergoing General Anesthesia
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 100
- Registration Number
- NCT04908592
- Locations
- 🇪🇬
Ain-Shams University Hospitals, Cairo, Egypt
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT04907227
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University ( Site 1319), Xiamen, Fujian, China
🇨🇳Hunan Cancer Hospital ( Site 1320), Changsha, Hunan, China
🇨🇳The Second Affiliated Hospital of Zhejiang University School of Medicine ( Site 1309), Hangzhou, Zhejiang, China
Pre-emptive Dexamethasone in Hip Arthroplasty
- Conditions
- Postoperative Pain
- Interventions
- Drug: Normal salineDrug: Dexamethasone
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 83
- Registration Number
- NCT04898920
- Locations
- 🇪🇬
Faculty of Medicine, Tanta, Algharbia, Egypt
Radiosurgery Before Surgery for the Treatment of Brain Metastases
- Conditions
- Metastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Emory University
- Target Recruit Count
- 20
- Registration Number
- NCT04895592
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Biological: LemzoparlimabDrug: DexamethasoneBiological: DaratumumabDrug: CarfilzomibDrug: Pomalidomide
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT04895410
- Locations
- 🇺🇸
Moffitt Cancer Center /ID# 229939, Tampa, Florida, United States
🇺🇸Norton Cancer Institute - St Matthews /ID# 229319, Louisville, Kentucky, United States
🇺🇸University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 229309, Ann Arbor, Michigan, United States
Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 35
- Registration Number
- NCT04892446
- Locations
- 🇺🇸
US Oncology, Inc., IRB, Fairfax, Virginia, United States
🇺🇸US San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
Comparison Between Adjuvants Added to Bupivacaine in Adductor Canal Block
- Conditions
- Anesthesia
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 120
- Registration Number
- NCT04892420
- Locations
- 🇪🇬
Ismail Mohammed Ibrahim, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.